

Maria Jose Morilla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8955732/publications.pdf>

Version: 2024-02-01

55
papers

1,585
citations

236612

25
h-index

315357

38
g-index

55
all docs

55
docs citations

55
times ranked

2197
citing authors

#	ARTICLE	IF	CITATIONS
1	Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 139, 190-198.	2.5	118
2	Highly deformable and highly fluid vesicles as potential drug delivery systems: theoretical and practical considerations. <i>International Journal of Nanomedicine</i> , 2013, 8, 3171.	3.3	89
3	On the mechanism of hepatic transendothelial passage of large liposomes. <i>FEBS Letters</i> , 1999, 448, 193-196.	1.3	70
4	Nanotechnological approaches against Chagas disease. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 576-588.	6.6	64
5	Sunlight triggered photodynamic ultradeformable liposomes against <i>Leishmania braziliensis</i> are also leishmanicidal in the dark. <i>Journal of Controlled Release</i> , 2010, 147, 368-376.	4.8	61
6	Drug delivery systems against leishmaniasis? Still an open question. <i>Expert Opinion on Drug Delivery</i> , 2008, 5, 805-823.	2.4	60
7	Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents. <i>International Journal of Pharmaceutics</i> , 2009, 380, 189-200.	2.6	57
8	Nanomolar cationic dendrimeric sulfadiazine as potential antitoxoplasmic agent. <i>International Journal of Pharmaceutics</i> , 2006, 326, 160-168.	2.6	53
9	Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis. <i>Nanomedicine</i> , 2015, 10, 465-481.	1.7	52
10	Ultradeformable archaeosomes as new topical adjuvants. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2012, 8, 1319-1328.	1.7	51
11	Intravenous liposomal benznidazole as trypanocidal agent: increasing drug delivery to liver is not enough. <i>International Journal of Pharmaceutics</i> , 2004, 278, 311-318.	2.6	50
12	Etanidazole in pH-sensitive liposomes: Design, characterization and in vitro/in vivo anti-Trypanosoma cruzi activity. <i>Journal of Controlled Release</i> , 2005, 103, 599-607.	4.8	46
13	In vitro phototoxicity of ultradeformable liposomes containing chloroaluminum phthalocyanine against New World <i>Leishmania</i> species. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2012, 117, 157-163.	1.7	46
14	Development and in vitro characterisation of a benznidazole liposomal formulation. <i>International Journal of Pharmaceutics</i> , 2002, 249, 89-99.	2.6	42
15	Increased brain radioactivity by intranasal ³² P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels. <i>International Journal of Nanomedicine</i> , 2012, 7, 1373.	3.3	40
16	Topical and mucosal liposomes for vaccine delivery. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2011, 3, 356-375.	3.3	38
17	Archaeosomes made of Halorubrum tebenquichensetotal polar lipids: a new source of adjuvancy. <i>BMC Biotechnology</i> , 2009, 9, 71.	1.7	36
18	The anti MRSA biofilm activity of <i>Thymus vulgaris</i> essential oil in nanovesicles. <i>Phytomedicine</i> , 2019, 57, 339-351.	2.3	34

#	ARTICLE	IF	CITATIONS
19	Photodynamic ultradeformable liposomes: Design and characterization. <i>International Journal of Pharmaceutics</i> , 2007, 330, 183-194.	2.6	31
20	Selective cytotoxicity of PAMAM G5 core–PAMAM G2.5 shell tecto-dendrimers on melanoma cells. <i>International Journal of Nanomedicine</i> , 2012, 7, 4121.	3.3	31
21	Uptake and intracellular traffic of siRNA dendriplexes in glioblastoma cells and macrophages. <i>International Journal of Nanomedicine</i> , 2011, 6, 2715.	3.3	30
22	Surviving nebulization-induced stress: dexamethasone in pH-sensitive archaeosomes. <i>Nanomedicine</i> , 2016, 11, 2103-2117.	1.7	30
23	Physicochemical characterization and cytotoxic studies of nonionic surfactant vesicles using sucrose esters as oral delivery systems. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 117, 1-6.	2.5	29
24	Ultra-small solid archaeolipid nanoparticles for active targeting to macrophages of the inflamed mucosa. <i>Nanomedicine</i> , 2017, 12, 1165-1175.	1.7	26
25	Structural features of ultradeformable archaeosomes for topical delivery of ovalbumin. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 121, 281-289.	2.5	25
26	Ultradeformable Archaeosomes for Needle Free Nanovaccination with <i>Leishmania braziliensis</i> Antigens. <i>PLoS ONE</i> , 2016, 11, e0150185.	1.1	25
27	Superoxide dismutase in nanoarchaeosomes for targeted delivery to inflammatory macrophages. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 179, 479-487.	2.5	24
28	Avoiding failed reconstitution of ultradeformable liposomes upon dehydration. <i>International Journal of Pharmaceutics</i> , 2009, 372, 184-190.	2.6	22
29	Brain and muscle of Wistar rats are the main targets of intravenous dendrimeric sulfadiazine. <i>International Journal of Pharmaceutics</i> , 2008, 360, 204-212.	2.6	21
30	Bacterioruberin from Haloarchaea plus dexamethasone in ultra-small macrophage-targeted nanoparticles as potential intestinal repairing agent. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 191, 110961.	2.5	21
31	Benznidazole vs benznidazole in multilamellar liposomes: how different they interact with blood components?. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2005, 100, 213-219.	0.8	19
32	Enhanced photodynamic leishmanicidal activity of hydrophobic zinc phthalocyanine within archaeolipids containing liposomes. <i>International Journal of Nanomedicine</i> , 2014, 9, 3335.	3.3	19
33	Topical vaccination with super-stable ready to use nanovesicles. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 152, 114-123.	2.5	19
34	Carrier Deformability in Drug Delivery. <i>Current Pharmaceutical Design</i> , 2016, 22, 1118-1134.	0.9	19
35	Archaeosomes display immunoadjuvant potential for a vaccine against Chagas disease. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 409-412.	1.4	18
36	Nebulizing novel multifunctional nanovesicles: the impact of macrophage-targeted-pH-sensitive archaeosomes on a pulmonary surfactant. <i>Journal of Materials Chemistry B</i> , 2017, 5, 8083-8095.	2.9	18

#	ARTICLE	IF	CITATIONS
37	In vitro activity of Etanidazole against the protozoan parasite Trypanosoma cruzi. Memorias Do Instituto Oswaldo Cruz, 2004, 99, 233-235.	0.8	15
38	Make It Simple: (SR-A1+TLR7) Macrophage Targeted NANOarchaeosomes. Frontiers in Bioengineering and Biotechnology, 2018, 6, 163.	2.0	15
39	Fast Biofilm Penetration and Anti-PAO1 Activity of Nebulized Azithromycin in Nanoarchaeosomes. Molecular Pharmaceutics, 2020, 17, 70-83.	2.3	14
40	Liposomal Benznidazole: A High-Performance Liquid Chromatographic Determination for Biodistribution Studies. Journal of Chromatographic Science, 2003, 41, 405-409.	0.7	13
41	Ultradeformable phospholipid vesicles as a drug delivery system: a review. Research and Reports in Transdermal Drug Delivery, 0, , 55.	0.0	13
42	G5G2.5 core-shell dendrimer specifically targets reactive glia in brain ischemia. Journal of Neurochemistry, 2018, 144, 748-760.	2.1	12
43	Macrophage apoptosis using alendronate in targeted nanoarchaeosomes. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 160, 42-54.	2.0	12
44	The Intervention of Nanotechnology Against Epithelial Fungal Diseases. Journal of Biomaterials and Tissue Engineering, 2013, 3, 70-88.	0.0	12
45	M Cells Prefer Archaeosomes: An In Vitro/In Vivo Snapshot Upon Oral Gavage in Rats. Current Drug Delivery, 2011, 8, 320-329.	0.8	11
46	Enhanced antimelanoma activity of methotrexate and zoledronic acid within polymeric sandwiches. Colloids and Surfaces B: Biointerfaces, 2014, 122, 19-29.	2.5	11
47	Novel imiquimod nanovesicles for topical vaccination. Colloids and Surfaces B: Biointerfaces, 2019, 174, 536-543.	2.5	8
48	Reparation of an Inflamed Air-Liquid Interface Cultured A549 Cells with Nebulized Nanocurcumin. Pharmaceutics, 2021, 13, 1331.	2.0	7
49	Nanomediical Therapeutic and Prophylaxis Strategies Against Intracellular Protozoa in the Americas. , 2015, , 297-317.		2
50	Enhancing the anti-psoriatic activity of vitamin D3 employing nanostructured archaeolipid carriers. Journal of Drug Delivery Science and Technology, 2022, 73, 103455.	1.4	2
51	Nanotoxicity of Lipid-Based Nanomedicines. , 2018, , 133-165.		1
52	Preclinical autophagy modulatory nanomedicines: big challenges, slow advances. Expert Opinion on Drug Delivery, 2021, 18, 1415-1434.	2.4	1
53	Toll like receptors agonists-based nanomedicines as veterinary immunotherapies. Precision Nanomedicine, 0, , .	0.4	1
54	Reparation of an Inflamed Air-Liquid Interface Cultured A549 Cells with Nebulized Nanocurcumin. Pharmaceutics, 2021, 13, .	2.0	1

#	ARTICLE	IF	CITATIONS
55	Intracellular Bacteria and Protozoa. Fundamental Biomedical Technologies, 2011, , 745-811.	0.2	0